A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells

References

• Criscitiello C, Morganti S, Curigliano G. Antibody–drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021;14(1):20. doi:10.1186/s13045-021-01035-z. PMID: 33509252.
   PubMed Web of Science ®Google Scholar
• Rios-Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, Marrero A, Chen C, Strout P, Mulgrew K, McGlinchey K, et al. Antibody–drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple Immunotherapies. Cancer Research. 2017;77(10):2686–16. doi:10.1158/0008-5472.CAN-16-2854. PMID: 28283653.
   PubMed Web of Science ®Google Scholar
• Gerber HP, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect? Biochem Pharmacol. 2016;102:1–6. doi:10.1016/j.bcp.2015.12.008. PMID: 26686577.
   PubMed Web of Science ®Google Scholar
• Iwata TN, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T. A HER2-targeting antibody–drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol Cancer Ther. 2018;17(7):1494–503. doi:10.1158/1535-7163.MCT-17-0749. PMID: 29703841.
   PubMed Web of Science ®Google Scholar
• Montes de Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, Seestaller-Wehr L, Kaczynski H, Shi H, Dobrzynski E, et al. Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol Cancer Ther. 2021;20(10):1941–55. doi:10.1158/1535-7163.MCT-21-0035. PMID: 34253590.
   PubMed Web of Science ®Google Scholar
• Yaghoubi S, Karimi MH, Lotfinia M, Gharibi T, Mahi-Birjand M, Kavi E, Hosseini F, Sineh Sepehr K, Khatami M, Bagheri N, et al. Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy. J Cell Physiol. 2020;235(1):31–64. doi:10.1002/jcp.28967. PMID: 31215038.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J ImmunoTher Cancer. 2020;8(1):e000337. doi:10.1136/jitc-2019-000337. PMID: 32209603.
   PubMed Web of Science ®Google Scholar
• Aaes TL, Vandenabeele P. The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses. Cell Death Differ. 2021;28:843–60. doi:10.1038/s41418-020-00658-y. PMID: 33214663.
   PubMed Web of Science ®Google Scholar
• Almanza A, Carlesso A, Chintha C, Creedican S, Doultsinos D, Leuzzi B, Luis A, McCarthy N, Montibeller L, More S, et al. Endoplasmic reticulum stress signalling - from basic mechanisms to clinical applications. FEBS J. 2019;286(2):241–78. doi:10.1111/febs.14608. PMID: 30027602.
   PubMed Web of Science ®Google Scholar
• Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat Rev Cancer. 2021;21:71–88. doi:10.1038/s41568-020-00312-2. PMID: 33214692.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860–75. doi:10.1038/nrc3380. PMID: 23151605.
   PubMed Web of Science ®Google Scholar
• Muller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, Savic S, Harbeck N, Nitz U, Gluz O, et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Translational Med. 2015;7(315):315ra188. doi:10.1126/scitranslmed.aac4925. PMID: 26606967.
   PubMed Web of Science ®Google Scholar
• Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67:173–85. doi:10.1248/cpb.c18-00744. PMID: 30827997.
   PubMed Web of Science ®Google Scholar
• Drake PM, Rabuka D. Recent developments in ADC technology: preclinical studies signal future clinical trends. BioDrugs. 2017;31:521–31. doi:10.1007/s40259-017-0254-1. PMID: 29119409.
   PubMed Web of Science ®Google Scholar
• Mahalingaiah PK, Ciurlionis R, Durbin KR, Yeager RL, Philip BK, Bawa B, Mantena SR, Enright BP, Liguori MJ, Van Vleet TR. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacology & Therapeutics. 2019;200:110–25. doi:10.1016/j.pharmthera.2019.04.008. PMID: 31028836.
   PubMed Web of Science ®Google Scholar
• Ferraro E, Drago JZ, Modi S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res. 2021;23:84. doi:10.1186/s13058-021-01459-y. PMID: 34380530.
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab — mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39–51. doi:10.1056/NEJMra043186. PMID: 17611206.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, Wang X, Li M, Lu W, Zeng G, et al. cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity. Journal Of Clinical Investigation. 2019;129(11):4850–62. doi:10.1172/JCI127471. PMID: 31408442.
   PubMed Web of Science ®Google Scholar
• Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci. 2019;110:2080–89. doi:10.1111/cas.14069. PMID: 31102428.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55. doi:10.1016/S1471-4906(02)02302-5.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008;118:1991–2001. doi:10.1172/JCI35180. PMID: 18523649.
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295–307. doi:10.1038/nri1806. PMID: 16557261.
   PubMed Web of Science ®Google Scholar
• Wu J, Waxman DJ. Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett. 2018;419:210–21. doi:10.1016/j.canlet.2018.01.050. PMID: 29414305.
   PubMed Web of Science ®Google Scholar
• Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology. 2017;6:e1386829. doi:10.1080/2162402X.2017.1386829. PMID: 29209573.
   PubMed Web of Science ®Google Scholar
• Kersten K, Salvagno C, de Visser KE. Exploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapy. Front Immunol. 2015;6:516. doi:10.3389/fimmu.2015.00516. PMID: 26500653.
   PubMed Web of Science ®Google Scholar
• Couper KN, Lanthier PA, Perona-Wright G, Kummer LW, Chen W, Smiley ST, Mohrs M, Johnson LL. Anti-CD25 antibody-mediated depletion of effector T cell populations enhances susceptibility of mice to acute but not chronic Toxoplasma gondii infection. J Immunol. 2009;182:3985–94. doi:10.4049/jimmunol.0803053. PMID: 19299696.
   PubMed Web of Science ®Google Scholar
• Willinghamm MD, Brodt MD, Lee KL, Stephens AL, Ye J, Silva MJ. Age-related changes in bone structure and strength in female and male BALB/c mice. Calcif Tissue Int. 2010;86:470–83. doi:10.1007/s00223-010-9359-y. PMID: 20405109.
   PubMed Web of Science ®Google Scholar
• de Miguel M, Calvo E. Clinical challenges of immune checkpoint inhibitors. Cancer Cell. 2020;38:326–33. doi:10.1016/j.ccell.2020.07.004. PMID: 32750319.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–55. doi:10.1126/science.aar4060. PMID: 29567705.
   PubMed Web of Science ®Google Scholar
• Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51:4187–91.
   PubMed Web of Science ®Google Scholar
• West AP, Khoury-Hanold W, Staron M, Tal MC, Pineda CM, Lang SM, Bestwick M, Duguay BA, Raimundo N, MacDuff DA, et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature. 2015;520(7548):553–57. doi:10.1038/nature14156. PMID: 25642965.
   PubMed Web of Science ®Google Scholar